Kiniksa Pharmaceuticals Q4 Earnings Assessment
Benzinga Insights 8 months ago
Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported its Q4 earnings results on Tuesday, February 24, 2026 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Kiniksa Pharmaceuticals missed estimated earnings by -51.43%, reporting an EPS of $0.17 versus an estimate of $0.35.
Revenue was up $79.59 million from the same period last year.
Previous Earnings Records
The company missed on EPS by $0.12 in the last quarter, resulting in a 5.2% drop share price change the following day.
Here's a look at Kiniksa Pharmaceuticals's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.35 | 0.21 | 0.28 | 0.13 |
| EPS Actual | 0.23 | 0.23 | 0.11 | -0.12 |
| Revenue Estimate | 166.84M | 145.24M | 131.71M | 123.38M |
| Revenue Actual | 180.85M | 156.80M | 137.78M | 122.54M |
To track all earnings releases for Kiniksa Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.